171 related articles for article (PubMed ID: 37460832)
1. MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent way.
Fang S; Zheng L; Chen X; Guo X; Ding Y; Ma J; Ding J; Chen W; Yang Y; Chen M; Zhao Z; Tu J; Ji J
Hepatol Int; 2023 Dec; 17(6):1500-1518. PubMed ID: 37460832
[TBL] [Abstract][Full Text] [Related]
2. LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling.
Cheng Y; Hou T; Ping J; Chen T; Yin B
J Exp Clin Cancer Res; 2018 Sep; 37(1):228. PubMed ID: 30219064
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
4. TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma.
Dong Q; Fu L; Zhao Y; Xie C; Li Q; Wang E
Oncotarget; 2017 Feb; 8(9):15689-15703. PubMed ID: 28152516
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA LOC107985656 represses the proliferation of hepatocellular carcinoma cells through activation of the tumor-suppressive Hippo pathway.
Zeng Y; Xu Q; Xu N
Bioengineered; 2021 Dec; 12(1):7964-7974. PubMed ID: 34565286
[TBL] [Abstract][Full Text] [Related]
6. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
[TBL] [Abstract][Full Text] [Related]
7. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
[TBL] [Abstract][Full Text] [Related]
8. A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1.
Ni W; Zhang Y; Zhan Z; Ye F; Liang Y; Huang J; Chen K; Chen L; Ding Y
J Hematol Oncol; 2017 Apr; 10(1):91. PubMed ID: 28420424
[TBL] [Abstract][Full Text] [Related]
9. The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4.
Chen W; Hu L; Lu X; Wang X; Zhao C; Guo C; Li X; Ding Y; Zhao H; Tong D; Wang L; Huang C
Breast Cancer Res Treat; 2023 Oct; 201(3):353-366. PubMed ID: 37433992
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells.
Wang C; Zhu ZM; Liu CL; He XJ; Zhang HY; Dong JH
Mol Med Rep; 2015 Jun; 11(6):4101-8. PubMed ID: 25625370
[TBL] [Abstract][Full Text] [Related]
12. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
13. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
Li H; Gai L; Wu Z; Li F
Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864
[TBL] [Abstract][Full Text] [Related]
14. SEPT6 drives hepatocellular carcinoma cell proliferation, migration and invasion via the Hippo/YAP signaling pathway.
Fan Y; Du Z; Ding Q; Zhang J; Op Den Winkel M; Gerbes AL; Liu M; Steib CJ
Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33846777
[TBL] [Abstract][Full Text] [Related]
15. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
Lu S; Yao Y; Xu G; Zhou C; Zhang Y; Sun J; Jiang R; Shao Q; Chen Y
Cell Death Dis; 2018 May; 9(6):646. PubMed ID: 29844385
[TBL] [Abstract][Full Text] [Related]
16. CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.
Hao X; Zhang Y; Shi X; Liu H; Zheng Z; Han G; Rong D; Zhang C; Tang W; Wang X
J Exp Clin Cancer Res; 2022 Sep; 41(1):281. PubMed ID: 36131287
[TBL] [Abstract][Full Text] [Related]
17. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.
Liang XD; Dai YC; Li ZY; Gan MF; Zhang SR; Yin-Pan ; Lu HS; Cao XQ; Zheng BJ; Bao LF; Wang DD; Zhang LM; Ma SL
PLoS One; 2014; 9(6):e97739. PubMed ID: 24905462
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta1 suppresses hepatocellular carcinoma proliferation via activation of Hippo signaling.
Zhang X; Fan Q; Li Y; Yang Z; Yang L; Zong Z; Wang B; Meng X; Li Q; Liu J; Li H
Oncotarget; 2017 May; 8(18):29785-29794. PubMed ID: 28076850
[TBL] [Abstract][Full Text] [Related]
19. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
Hashiba T; Yamashita T; Okada H; Nio K; Hayashi T; Asahina Y; Hayashi T; Terashima T; Iida N; Takatori H; Shimakami T; Kawaguchi K; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Takamura H; Ohta T; Honda M; Kaneko S
Cell Mol Gastroenterol Hepatol; 2020; 10(2):269-285. PubMed ID: 32169577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
